Overview
Date:
6th November 2024, Wednesday
Time:
10:00 am - 11:00 am (Bangkok)
11:00 am - 12:00 pm (Singapore)
12:00 pm – 01:00 pm (Seoul / Tokyo)
02:00 pm - 03:00 pm (Melbourne)
04:00 pm - 05:00 pm (Auckland)
We understand that our webinar timing may not suit your busy schedule. Please feel free to register to get the on-demand recording link once it is ready.
What does it take to bring genomics in house? How can an exome or genome backbone help in streamlining laboratory research workflows?
In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research.
With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene, laboratories can now create comprehensive assays to enable the latest genomic discoveries.
Whether you are looking to future proof your laboratory workflows or bridge from panels to new frontiers of the genome. Join us to find out more about Illumina’s solution for rare and inherited disease research. No matter where your laboratory is on its genomics journey, Illumina can provide the tools and support from a single trusted partner.
The key things you will learn in this webinar are:
- How NextSeq’s flexibility and workflow benefit lab functionality.
- How DRAGEN and Emedgene can help reduce bottlenecks in analysis and reporting.
- How an exome or genome backbone can help futureproof laboratory workflows.
 |
Dr Anthony Beckhouse |
Anthony joined Illumina in 2019 and manages the Regional Product Marketing team for Illumina Sequencing instruments, consumables, library prep, software and Microarrays for the Asia Pacific, Middle East and Africa regions. He has had many roles in the biotech sales, technology development and technical support industry over the last 12 years and has been the industry representative on several successful grant applications. Prior to his career in Industry, he had a seven year academic career at University of Queensland and Griffith University studying the immune cell response to pathogenic molecules and was an active participant in the highly successful FANTOM 4 and 5 projects led out of RIKEN in Japan. |
 |
Dr Michael Fietz |
Dr Michael Fietz has a career of over 30 years in molecular genetics, working in the areas of research, academia and diagnostic pathology, before commencing work with Illumina in 2018. Through this he has developed a deep understanding of molecular genetic techniques and applications, with a particular focus on NGS data processing, analysis, interpretation and reporting. As part of the Illumina team, Michael has worked to assist clinical laboratories in the integration of appropriate informatics systems for the management, analysis, and reporting of NGS data. His current role is to support our strategic customers and large-scale projects in applying clinical informatics tools to handle high-throughput NGS applications. |